Skip to Main Content

Paper Details

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir.
medRxiv
5
2022
Author NameAffiliation
Elodie GhedinNational Institute of Allergy and Infectious Diseases, National Institutes of Health
  • 1 - 1

Datasets

Release 1.2